X4 Pharmaceuticals, Inc.
XFORHealthcareNASDAQBiotechnology · Last scanned Jun 3, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, X4 Pharmaceuticals, Inc. focuses on Biotechnology services and products. X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. Valued at $381.1M, XFOR is a small-cap name in its sector. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome.
Market Cap
$381.1M
Beta
0.32
P/E (TTM)
—
P/E (Fwd)
-4.42
EPS (TTM)
$-2.07
EPS (Fwd)
$-0.91
ROE
-104.2%
ROA
-28.3%
Cash
$233.7M
Total Debt
$77.3M
Free CF
-$55.2M
52W Change
0.0%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $233.7M in cash comfortably exceeding the $77.3M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$55.2M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -104.2%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
XFOR's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing XFOR.